CA2599436A1 - Mitotic kinesin inhibitors - Google Patents

Mitotic kinesin inhibitors Download PDF

Info

Publication number
CA2599436A1
CA2599436A1 CA002599436A CA2599436A CA2599436A1 CA 2599436 A1 CA2599436 A1 CA 2599436A1 CA 002599436 A CA002599436 A CA 002599436A CA 2599436 A CA2599436 A CA 2599436A CA 2599436 A1 CA2599436 A1 CA 2599436A1
Authority
CA
Canada
Prior art keywords
alkyl
aryl
cycloalkyl
heterocyclyl
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002599436A
Other languages
English (en)
French (fr)
Inventor
Paul J. Coleman
Christopher D. Cox
George D. Hartman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2599436A1 publication Critical patent/CA2599436A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002599436A 2005-03-16 2006-03-10 Mitotic kinesin inhibitors Abandoned CA2599436A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66222605P 2005-03-16 2005-03-16
US60/662,226 2005-03-16
PCT/US2006/008482 WO2006101761A2 (en) 2005-03-16 2006-03-10 Mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
CA2599436A1 true CA2599436A1 (en) 2006-09-28

Family

ID=37024314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002599436A Abandoned CA2599436A1 (en) 2005-03-16 2006-03-10 Mitotic kinesin inhibitors

Country Status (7)

Country Link
US (1) US7625936B2 (enExample)
EP (1) EP1861366A2 (enExample)
JP (1) JP2008535803A (enExample)
CN (1) CN101142183A (enExample)
AU (1) AU2006227854A1 (enExample)
CA (1) CA2599436A1 (enExample)
WO (1) WO2006101761A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629373B2 (en) 2005-04-07 2009-12-08 Merck & Co. Inc. Mitotic kinesin inhibitors
PE20091349A1 (es) 2007-10-19 2009-09-07 Schering Corp Compuestos derivados de espiro 1,3,4-tiadiazol como inhibidores de la actividad quinesina ksp
PL214017B1 (pl) * 2009-09-11 2013-06-28 Univ Adama Mickiewicza Nowe (E)-styrylo-alkinylopodstawione zwiazki krzemu oraz sposób otrzymywania (E)-styrylo-alkinylopodstawionych zwiazków krzemu
CN111116419B (zh) * 2014-03-04 2022-03-29 江苏豪森药业集团有限公司 曲前列尼尔中间体及其制备工艺
CN111138338A (zh) * 2020-01-20 2020-05-12 中国人民解放军61699部队 一种光催化氟烷基吲哚啉的合成方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Also Published As

Publication number Publication date
EP1861366A2 (en) 2007-12-05
AU2006227854A1 (en) 2006-09-28
CN101142183A (zh) 2008-03-12
JP2008535803A (ja) 2008-09-04
US7625936B2 (en) 2009-12-01
WO2006101761A3 (en) 2007-03-08
WO2006101761A2 (en) 2006-09-28
US20080194582A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
AU2003297230B2 (en) Mitotic kinesin inhibitors
US7629373B2 (en) Mitotic kinesin inhibitors
US7625936B2 (en) Mitotic kinesin inhibitors
US20080045492A1 (en) Mitotic Kinesin Inhibitors
US7595337B2 (en) Mitotic kinesin inhibitors
US7723365B2 (en) Mitotic kinesin inhibitors
US7618971B2 (en) Mitotic kinesin inhibitors
US7553838B2 (en) Mitotic kinesin inhibitors
EP1765830B1 (en) Mitotic kinesin inhibitors
US7732472B2 (en) Mitotic kinesin inhibitors
US20080207693A1 (en) Mitotic Kinesin Inhibitors
US7718687B2 (en) Prodrugs of mitotic kinesin inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued